Atomo Diagnostics Halts Trading Ahead of Key FDA Decision on FebriDx

An announcement from Atomo Diagnostics Ltd. ( (AU:AT1) ) is now available.

Atomo Diagnostics has requested a trading halt on its ASX-listed securities pending an announcement on the U.S. Food and Drug Administration’s response to the CLIA waiver application for the FebriDx® test submitted by Lumos Diagnostics. As Atomo exclusively supplies the Pascal cassettes used in FebriDx®, the FDA decision is expected to materially affect the volume of FebriDx® sales and, by extension, Atomo’s revenue outlook, prompting the company to pause trading to manage its continuous disclosure obligations and avoid uninformed market activity.

The trading halt will remain in place until either the start of normal trading on Monday, 30 March 2026, or the earlier release of the FDA-related update to the market, with Atomo indicating it expects to provide details before trading resumes. The move underscores the company’s operational and financial sensitivity to the regulatory trajectory of FebriDx® in the U.S. market, signaling a potentially significant development for shareholders and commercial partners once the regulatory outcome is disclosed.

The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Ltd is an Australia-based medical diagnostics company listed on the ASX under the ticker AT1. The company acts as the exclusive licensor, manufacturer and supplier of Pascal cassettes used in Lumos Diagnostics’ FebriDx® rapid test, exposing it to U.S. regulatory outcomes that directly influence test demand and related cassette sales.

Average Trading Volume: 1,573,814

Technical Sentiment Signal: Buy

Current Market Cap: A$28.36M

For a thorough assessment of AT1 stock, go to TipRanks’ Stock Analysis page.